HALO News and Press, Halozyme Therapeutics Inc. From 05/06/19

SAN DIEGO , May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A. Armour , M.B. Ch.B., B....

Not for Distribution to U.S. Newswire Servicers or For Dissemination in the United States Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has qualified to trade on the OTCQX® Best Market. Halo Labs upgrades to O...

Not for Distribution to U.S. Newswire Servicers or For Dissemination in the United States Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has qualified to trade on the OTCQX® Best Market. Halo Labs upgrades to O...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio...

SAN DIEGO , April 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the first quarter 2019 on Tuesday, May 7 at 4:30 p.m. ET / 1:30 ...

SAN DIEGO , March 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences. The 39 th Annual Cowen Healthcare Conference on Monday, Mar...

SAN DIEGO , Feb. 28, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administ...

Halozyme Therapeutics, Inc. (HALO) Q4 2018 Earnings Conference Call February 21, 2019 04:30 PM ET Company Participants Al Kildani - VP of IR and Corporate Communications Dr. Helen Torley - President, CEO & Director Laurie Stelzer - SVP & CFO Conference Call Participant...

Halozyme Therapeutics (NASDAQ: HALO ): Q4 GAAP EPS of -$0.01 beats by $0.02 . Revenue of $60.2M (-68.2% Y/Y) beats by $0.45M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,